Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?

JCO Precis Oncol. 2024 May:8:e2400113. doi: 10.1200/PO.24.00113.

Abstract

Gong et al present two NCI-MATCH tumor-agnostic trials evaluating erdafitinib for FGFR-altered cancers, marking steppingstones in precision oncology.

Publication types

  • Editorial

MeSH terms

  • Humans
  • Mutation*
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Precision Medicine
  • Pyrazoles / therapeutic use
  • Quinoxalines*
  • Receptors, Fibroblast Growth Factor / genetics

Substances

  • Receptors, Fibroblast Growth Factor
  • erdafitinib
  • Pyrazoles
  • Quinoxalines